11/13
07:20 am
clrb
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/6
08:38 am
clrb
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 [Yahoo! Finance]
Low
Report
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 [Yahoo! Finance]
11/6
08:05 am
clrb
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
Medium
Report
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
10/27
08:30 am
clrb
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
High
Report
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
10/14
08:58 am
clrb
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research [Yahoo! Finance]
Low
Report
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research [Yahoo! Finance]
10/14
08:30 am
clrb
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
Low
Report
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
10/7
08:49 am
clrb
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million [Yahoo! Finance]
Low
Report
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million [Yahoo! Finance]
10/7
08:30 am
clrb
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
High
Report
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
10/6
07:23 am
clrb
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) [Yahoo! Finance]
Medium
Report
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) [Yahoo! Finance]
10/6
07:00 am
clrb
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
Low
Report
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
9/30
08:30 am
clrb
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Low
Report
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
9/24
08:56 am
clrb
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) [Yahoo! Finance]
Medium
Report
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) [Yahoo! Finance]
9/24
08:30 am
clrb
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
Medium
Report
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
9/11
08:49 am
clrb
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 [Yahoo! Finance]
Low
Report
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 [Yahoo! Finance]
9/11
08:05 am
clrb
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Low
Report
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
9/9
08:28 am
clrb
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit [Yahoo! Finance]
Medium
Report
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit [Yahoo! Finance]
9/9
08:05 am
clrb
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Medium
Report
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit